热门资讯> 正文
Absci临床试验加速攀升
2025-10-15 23:31
- Absci (NASDAQ:ABSI) shares soared ~18% on Wednesday after the AI-focused biotech announced a faster timeline to begin a proof-of-concept trial for ABS-201, an experimental therapy for an inherited form of hair loss called androgenetic alopecia.
- Vancouver, Washington-based Absci (NASDAQ:ABSI) said that the anti-PRLR antibody will enter a Phase 1/2a trial in early December, as opposed to its prior plan to begin the study in early 2026. The company remains on track to share an interim efficacy readout from the study in H2 2026.
- According to Absci (NASDAQ:ABSI), ABS-201 has outperformed the FDA-approved hair loss therapy minoxidil in preclinical studies, indicating a superior and statistically significant hair regrowth. Androgenetic alopecia affects an estimated ~80M Americans, leading to male-pattern or female-pattern hair loss.
More on Absci
- Absci Corporation: ABS-101 Has Both First-Gen And Next-Gen Competitors
- Absci Corporation (ABSI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Absci: Still A Work In Progress, Fighting To Survive
- Absci spikes as J.P. Morgan starts at Buy ahead of key catalyst
- Absci collaborates with Oracle and AMD to speed up AI-led drug discovery
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
